Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer
Jinfeng Liu1, Chang Zhang2, Shuang Liu1
1Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Tianjin, 300060, China.
Abstract:
Tanshinone IIA (Tan IIA) was mainly used for cardiovascular disease treatment. Recent studies have demonstrated the role of Tan IIA for tumor treatment, but its mechanism remains unclear. At the first, the inhibitory effect of Tan IIA on 4T1 breast cancer cells was determined by CCK8 and colony formation assay. Then, a 4T1 BALB/c model of breast cancer was established to evaluate the anti-cancer effect of Tan IIA in vivo. Flow cytometry analysis and the TUNEL test were used to detect cell apoptosis in vitro and in vivo, respectively. The related targets and mechanisms of Tan IIA were predicted through network-based systems biology. At last, molecular docking and the molecular biological techniques were used to evaluate the predicted targets. Tan IIA displayed encouraging inhibitory influences on 4T1 cells after incubation for 24 h and showed a half-maximal inhibitory concentration (IC50) of 49.78 μM after 48-h incubation. After 23 days of treatment, the relative tumor volumes in the Tan IIA group were 65.53% inhibited compared with the control group. Furthermore, Tan IIA induced 4T1 cell apoptosis both in vivo and in vitro. The possible targets of Tan IIA for TNBC treatment were predicted with network-based systems biology, and results showed that TP53, NF-κB, AKT, MYC, and BCL-2 were the hub targets. The mechanism against breast cancer may be based on the P53 signaling pathway, the PI3K/Akt pathway, the MAPK signaling pathway, and the mTOR signaling pathways. Molecular docking analysis reveals that Tan IIA has a high affinity for p53, Bcl-2, and NF-κB1; the binding energies were - 6.92, - 6.07, and - 6.28 kcal/mol, respectively. The predicted proteins were further validated using Western blotting. Increased expression of phosphorylated p53 and p53 and decreased expression of Bcl-2 were found in Tan IIA-treated 4T1 cells. Tan IIA is potentially effective for the treatment of 4T1 breast cancer, and the molecular mechanism may be through enhancing the activity of p53 and decreasing Bcl-2 to suppress proliferation and promote apoptosis.
Insights
Tanshinone IIA effectively inhibits 4T1 breast cancer growth in vitro and in vivo by inducing apoptosis. This study reveals its mechanism involves modulating the p53 and Bcl-2 pathways, offering potential for triple-negative breast cancer treatment.
Area of Science:
- Pharmacology
- Oncology
- Systems Biology
Background:
- Tanshinone IIA (Tan IIA), primarily used for cardiovascular conditions, shows emerging potential in tumor treatment.
- The precise molecular mechanisms underlying Tan IIA's anti-cancer effects, particularly in breast cancer, require further elucidation.
Purpose of the Study:
- To investigate the anti-cancer efficacy of Tan IIA against 4T1 breast cancer cells and a corresponding in vivo model.
- To explore the underlying molecular targets and signaling pathways involved in Tan IIA's anti-tumor activity.
Main Methods:
- In vitro assays (CCK8, colony formation) and in vivo xenograft models were used to assess Tan IIA's inhibitory effects.
- Flow cytometry, TUNEL assays, network-based systems biology, molecular docking, and Western blotting were employed to elucidate mechanisms and targets.
Main Results:
- Tan IIA significantly inhibited 4T1 cell proliferation and tumor growth, with a 65.53% reduction in tumor volume in vivo.
- Tan IIA induced apoptosis in 4T1 cells both in vitro and in vivo.
- Network analysis identified TP53, NF-κB, AKT, MYC, and BCL-2 as key targets, with Tan IIA enhancing p53 activity and decreasing Bcl-2 expression.
Conclusions:
- Tan IIA demonstrates significant potential as an anti-cancer therapeutic for 4T1 breast cancer.
- The anti-tumor mechanism likely involves the p53 and PI3K/Akt signaling pathways, leading to suppressed proliferation and enhanced apoptosis.
More Related Videos
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Related Concept Videos
The Intrinsic Apoptotic Pathway
TGF - β Signaling Pathway
The Extrinsic Apoptotic Pathway
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
